For millions of workers, the day begins although the world is still dark. Whether We see a nurse starting a 6 a.m. Ward round, a baker prepping the first batch of sourdough, or a truck driver navigating highways before dawn, the struggle to maintain alertness during early shifts is a pervasive, often exhausting reality.
This chronic struggle is more than just “not being a morning person.” For many, it is a clinical condition known as Shift Function Disorder (SWD), a circadian rhythm sleep disorder that occurs when a person’s internal biological clock is misaligned with their required work schedule. The result is a debilitating cycle of excessive daytime sleepiness and insomnia when they actually have the chance to sleep.
While the standard response has long been a heavy reliance on caffeine, a recent study from Brigham and Women’s Hospital suggests that a pharmacological intervention called solriamfetol may offer a more stable alternative for those struggling with morning shift fatigue. By targeting the brain’s wakefulness systems more precisely than a cup of coffee, this medication could potentially reduce the safety risks and cognitive fog associated with early-hour labor.
The implications are significant. According to a 2021 international systematic review and meta-analysis, more than 25% of people working irregular hours experience symptoms consistent with Shift Work Disorder. When a quarter of the workforce in critical sectors—including emergency services and transportation—is operating under a cloud of sleep deprivation, the issue shifts from a personal inconvenience to a public health concern.
The Hidden Cost of the Early Shift
The human body is governed by a circadian rhythm, a 24-hour internal clock that regulates sleep, hormone release, and body temperature. When we are forced to wake up and perform complex tasks during the biological “night,” we are fighting millions of years of evolution. This misalignment does not just cause tiredness; it impairs executive function, slows reaction times, and increases the likelihood of workplace accidents.
In an office setting, a “micro-sleep” might result in a missed email or a typo. However, for those in high-stakes roles—such as police officers, airport ground crew, or heavy machinery operators—a few seconds of cognitive lapse can be catastrophic. The mental toll is equally heavy, often manifesting as irritability, anxiety, and a general sense of burnout that persists even on days off.
For most, the first line of defense is caffeine. While caffeine is effective at blocking adenosine receptors—the chemicals in the brain that signal sleepiness—it is a blunt instrument. High doses can lead to jitters, increased heart rate, and, most critically, a disruption of the very sleep the worker needs to recover. This creates a “caffeine loop” where the drug used to survive the shift prevents the restorative sleep required to function the next day.
How Solriamfetol Differs from Caffeine
Researchers at Brigham and Women’s Hospital sought to determine if solriamfetol, a wakefulness-promoting agent, could provide a more sustainable solution. Unlike caffeine, solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor (DNRI). It works by increasing the levels of these neurotransmitters in the brain, which are directly linked to alertness and arousal.
The medication is already FDA-approved for the treatment of excessive sleepiness in adults with narcolepsy and obstructive sleep apnea. The study aimed to see if these same mechanisms could be applied to the specific challenges of Shift Work Disorder.
In a controlled trial involving 78 participants with SWD, researchers administered solriamfetol to one group and a placebo to another over a four-week period. The findings were encouraging: those receiving the medication reported significantly lower levels of sleepiness and a marked increase in their ability to stay awake and alert during their working hours.
Crucially, both the participants and the observing physicians noted an improvement in overall functioning. Patients were better able to maintain an overview of their daily tasks and manage their responsibilities with greater cognitive clarity. Perhaps the most vital finding for long-term health was that solriamfetol did not appear to negatively impact the quality of the participants’ sleep—a common failure of traditional stimulants.
Comparative Impact: Caffeine vs. Solriamfetol
| Feature | Caffeine (High Dose) | Solriamfetol |
|---|---|---|
| Mechanism | Adenosine Receptor Antagonist | DNRI (Dopamine/Norepinephrine) |
| Onset/Duration | Rapid / Short-term | Consistent / Long-acting |
| Sleep Impact | Often disrupts sleep architecture | Minimal impact on sleep quality |
| Primary Side Effect | Jitters, tachycardia, “crash” | Varies; requires clinical oversight |
The Physician’s Perspective: A Tool, Not a Cure
As a physician, it is important to frame these results with a necessary degree of caution. While the data is promising, medication is a tool for management, not a cure for the underlying systemic issue. The biological drive for sleep is a critical signal from the body that it requires repair and recovery. Masking that signal with a pharmaceutical agent, while helpful for occupational safety, does not remove the long-term physiological stress of shift work.
There are also unanswered questions regarding the long-term use of DNRI agents for those without a primary sleep disorder like narcolepsy. We must investigate whether long-term reliance on such medications leads to tolerance or other cardiovascular effects over several years of use. The ethical question remains: should we be medicating the worker to fit an inflexible schedule, or should we be redesigning the schedule to fit the human worker?
For many, the ability to pursue a career—such as nursing or emergency medicine—should not be contingent on their innate chronotype (whether they are a “lark” or an “owl”). Solriamfetol represents a potential bridge, allowing individuals to perform their jobs safely and effectively without the debilitating “brain fog” that characterizes SWD.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication.
The next phase of research will likely focus on larger, long-term longitudinal studies to establish the safety profile of solriamfetol over extended periods of employment. Until then, the gold standard for managing early shifts remains a combination of strict sleep hygiene, strategic light exposure, and, for many, the familiar comfort of a morning coffee.
Do you struggle with the “morning fog” of an early shift? We invite you to share your experiences and thoughts on workplace wellness in the comments below.
